- Home
- SRAD vs CRNX Comparison
SRAD vs CRNX Comparison
Compare SRAD & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRAD
- CRNX
- Stock Information
- Founded
- SRAD 2001
- CRNX 2008
- Country
- SRAD Switzerland
- CRNX United States
- Employees
- SRAD N/A
- CRNX N/A
- Industry
- SRAD Computer Software: Programming Data Processing
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- SRAD Technology
- CRNX Health Care
- Exchange
- SRAD Nasdaq
- CRNX Nasdaq
- Market Cap
- SRAD 5.2B
- CRNX 5.2B
- IPO Year
- SRAD 2021
- CRNX 2018
- Fundamental
- Price
- SRAD $21.62
- CRNX $33.54
- Analyst Decision
- SRAD Strong Buy
- CRNX Strong Buy
- Analyst Count
- SRAD 12
- CRNX 12
- Target Price
- SRAD $23.17
- CRNX $73.36
- AVG Volume (30 Days)
- SRAD 1.2M
- CRNX 928.6K
- Earning Date
- SRAD 03-19-2025
- CRNX 05-08-2025
- Dividend Yield
- SRAD N/A
- CRNX N/A
- EPS Growth
- SRAD N/A
- CRNX N/A
- EPS
- SRAD 0.11
- CRNX N/A
- Revenue
- SRAD $1,145,621,700.00
- CRNX $1,039,000.00
- Revenue This Year
- SRAD $15.40
- CRNX $394.51
- Revenue Next Year
- SRAD $12.14
- CRNX $699.82
- P/E Ratio
- SRAD $193.02
- CRNX N/A
- Revenue Growth
- SRAD 26.09
- CRNX N/A
- 52 Week Low
- SRAD $9.17
- CRNX $31.65
- 52 Week High
- SRAD $23.49
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- SRAD 51.08
- CRNX 41.58
- Support Level
- SRAD $21.11
- CRNX $32.90
- Resistance Level
- SRAD $22.66
- CRNX $35.26
- Average True Range (ATR)
- SRAD 1.15
- CRNX 1.51
- MACD
- SRAD 0.07
- CRNX 0.15
- Stochastic Oscillator
- SRAD 54.72
- CRNX 39.38
About SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.